R Squared’s NovoCure NVCR Stock Holding History

R Squared’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,374	Closed	-$134K	–	659
2025 Q3	$134K	Buy	+10,374	New	+$139K	0.06%	422
2025 Q1	–	Sell	-230	Closed	-$6.85K	–	1090
2024 Q4	$6.85K	Buy	+230	New	+$4.87K	0.01%	1248

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

R Squared's NVCR Position: Q4 2025 in Review

R Squared sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 10,374 shares — an estimated $134K sold.

R Squared first reported a position in NVCR in Q4 2024 and held it in 2 quarters. The position peaked at $134K in Q3 2025. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

R Squared reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
R Squared sold 10,374 NovoCure shares in Q4 2025, an estimated $134K.
R Squared first reported a position in NovoCure in Q4 2024 and held it in 2 quarters.
R Squared's NovoCure position peaked at $134K in Q3 2025.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on R Squared's 13F filing for Q4 2025, filed 30 Jan 2026.